$2.32 billion is nowhere close to what CytoDyn would be purchased for and by "takeover" do you mean "buy out"?. Perhaps the licensing of HIV for that amount, but certainly not including cancer. The BOD knows that cancer is potentially worth multiples of what HIV is.